Phase 2
๐ Investigational Drug / Biologic
NCT05491525
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
๐ Arkansas Childrens Hospital โ Little Rock, Arkansas
View Study & Screener โ